Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors

Pharmacokinetics

1982 • 3,815 citations

Methotrexate: Distribution in Cerebrospinal Fluid after Intravenous, Ventricular and Lumbar Injections

1975 • 676 citations

The Current Status of Camptothecin Analogues as Antitumor Agents

1993 • 614 citations

A kinetic and Mechanistic Study of the Hydrolysis of Camptothecin and Some Analogues

1992 • 456 citations

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.

1992 • 363 citations

The structural basis of camptothecin interactions with human serum albumin: impact on drug stability

1994 • 316 citations

Camptothecins: from bench research to hospital wards.

1994 • 314 citations

Activity of Topotecan, a New Topoisomerase I Inhibitor, Against Human Tumor Colony-Forming Units In Vitro

1992 • 174 citations

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.

1994 • 166 citations

Lipid bilayer partitioning and stability of camptothecin drugs

1993 • 157 citations

Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients.

1984 • 149 citations

Cytosine arabinoside cerebrospinal fluid kinetics

1984 • 140 citations

Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa.

1989 • 136 citations

Phase I Clinical and Pharmacology Study of Topotecan Given Daily for 5 Consecutive Days to Patients With Advanced Solid Tumors, With Attempt at Dose Intensification Using Recombinant Granulocyte Colony-Stimulating Factor

1993 • 135 citations

Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia

1993 • 133 citations

Phase I study of topotecan for pediatric patients with malignant solid tumors.

1994 • 132 citations

Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer.

1992 • 128 citations

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor

1993 • 123 citations

A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days

1992 • 112 citations

Distribution of methotrexate in the cerebrospinal fluid and brain after intraventricular administration.

1977 • 108 citations

Distributed model for drug delivery to CSF and brain tissue

1983 • 105 citations

Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity.

1994 • 97 citations

Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection.

1977 • 97 citations

Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates.

1993 • 96 citations

Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.

1993 • 93 citations

Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.

1994 • 86 citations

Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts

1994 • 86 citations

Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution

1990 • 76 citations

Topoisomerase I Inhibitors: An Overview of the Camptothecin Analogs

1994 • 57 citations

A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid.

1994 • 54 citations

Pharmacology of Antineoplastic Agents in Cerebrospinal Fluid

1980 • 35 citations

Cerebrospinal fluid penetration of active metabolites of cyclophosphamide and ifosfamide in rhesus monkeys.

1988 • 33 citations